Mitsubishi UFJ Asset Management Co. Ltd. Buys 5,906 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,785 shares of the biopharmaceutical company’s stock after purchasing an additional 5,906 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.09% of Alnylam Pharmaceuticals worth $36,452,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $30,000. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $27,000. Ameritas Advisory Services LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $42,000. AlphaQuest LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $43,000. Finally, Parkside Financial Bank & Trust raised its position in Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ALNY shares. The Goldman Sachs Group boosted their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a report on Tuesday, September 16th. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $478.67.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 0.2%

Alnylam Pharmaceuticals stock opened at $441.70 on Tuesday. The firm has a market cap of $58.35 billion, a price-to-earnings ratio of -178.83 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a 50 day moving average price of $458.65 and a two-hundred day moving average price of $379.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $1.39 by $1.51. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s revenue for the quarter was up 149.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.50) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.